Multiple factors, including politics, are pressuring biotech stocks and ETFs this year. Election year posturing over drug prices represents a significant headwind for the healthcare sector and that is something biotech ETFs like IBB have already proven vulnerable to. Just go back to September 2015 and refer to Hillary Clinton’s Twitter feed.
Related: Resisting Biotech ETFs
According to Barron’s, some biotech stocks, including IBB holdings, have significantly larger foreign exposure than others. However, in many cases, direct exposure to the United Kingdom is limited.
For more information on the biotech sector, visit our biotechnology category.
iShares Nasdaq Biotechnology ETF
